Synchron is a pioneering clinical-stage company focused on developing an endovascular brain-computer interface (BCI) that enables individuals with paralysis to regain control over personal devices through a minimally invasive procedure. Founded in 2012, Synchron's innovative BCI technology, known as the Synchron Switch™, has received FDA Breakthrough Device Designation and is currently undergoing human clinical trials in the US and Australia. With recent funding of $75 million from prominent investors, Synchron aims to accelerate product development and achieve market approval for its groundbreaking technology, which has the potential to transform the lives of over 100 million people worldwide suffering from upper limb impairments. The company fosters a dynamic and collaborative work environment, dedicated to advancing life-changing technologies for individuals with disabilities.